IP Library Granted Patent US 8,518,875
Granted Patent B2
US 8,518,875 · App. 12/724,519 · Granted Aug 27, 2013

(Carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,518,875
App. No.
12/724,519
Granted
Aug 27, 2013
Kind
B2
Abstract

The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament.

Claims (44)

1. A compound of formula I

wherein;

R3 is H, F, Cl, Br, CF 3 , OCF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 3 -C 8 )-Cycloalkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R1 and R5 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R2 and R4 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, or (C 1 -C 6 )-alkyl;

R6 is OH, F, Cl, Br, CN, OCH 3 , OCF 3 , CH 3 , CF 3 , (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl,

wherein the alkyl is optionally substituted one or more times by OH, F, Cl, Br or CN;

R7 and R8 are H;

X is a C 2 alkylene substituted by one C 3 alkynyl group;

m is 0, 1, 2, 3 or 4;

and

R9 and R10 are, independently, H, (C 1 -C 6 )-alkyl or phenyl, wherein the alkyl is optionally substituted one or more times by F, Cl or Br, and the phenyl is optionally substituted one or more times by R6;

R12 is F, Cl, Br, CN, OH, O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, NR9R10, COOH, or COO—(C 1 -C 4 )-alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula:

wherein;

R3 is H, F, Cl, Br, CF 3 , OCF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 3 -C 8 )-Cycloalkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R1 and R5 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R2 and R4 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, or (C 1 -C 6 )-alkyl;

R6 is OH, F, Cl, Br, CN, OCH 3 , OCF 3 , CH 3 , CF 3 , (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl,

wherein the alkyl is optionally substituted one or more times by OH, F, Cl, Br or CN;

R7 and R8 are H; and

X is a C 2 alkylene substituted by one C 3 alkynyl group, where X is linked at position 4 to the ring;

or a pharmaceutically acceptable salt thereof.

3. A compound of the formula:

wherein;

R3 is H, F, Cl, Br, CF 3 , OCF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 3 -C 8 )-Cycloalkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R1 and R5 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R2 and R4 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, or (C 1 -C 6 )-alkyl;

R6 is OH, F, Cl, Br, CN, OCH 3 , OCF 3 , CH 3 , CF 3 , (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl,

wherein the alkyl is optionally substituted one or more times by OH, F, Cl, Br or CN;

R7 and R8 are H; and

X is a C 2 alkylene substituted by one C 3 alkynyl group;

or a pharmaceutically acceptable salt thereof.

4. A compound of the formula:

wherein;

R3 is H, F, Cl, Br, CF 3 , OCF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, (C 3 -C 8 )-Cycloalkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R1 and R5 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, phenyl, or O-phenyl, wherein the alkyl and phenyl are optionally substituted one or more times by R12;

R2 and R4 are, independently, H, F, Cl, Br, CF 3 , COOH, COO—(C 1 -C 6 )-alkyl, or (C 1 -C 6 )-alkyl;

R6 is OH, F, Cl, Br, CN, OCH 3 , OCF 3 , CH 3 , CF 3 , (C 1 -C 6 )-alkyl or O—(C 1 -C 6 )-alkyl,

wherein the alkyl is optionally substituted one or more times by OH, F, Cl, Br or CN;

R7 and R8 are H; and

X is a C 2 alkylene substituted by one C 3 alkynyl group, where X is linked at position 4 to the ring;

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2010
From: DEFOSSA, ELISABETH; KLABUNDE, THOMAS; DIETRICH, VIKTORIA; STENGELIN, SIEGFRIED; HASCHKE, GUIDO; HERLING, ANDREAS; KUHLMANN-GOTTKE, JOHANNA; BARTOSCHEK, STEFAN
To: SANOFI-AVENTIS
Reel/Frame 025038/0041 →